Total Payments
$58,659
2024 Payments
$13,229
Companies
32
Transactions
281
Medicare Patients
992
Medicare Billing
$110,228
Payment Breakdown by Category
Consulting$30,697 (52.3%)
Other$15,716 (26.8%)
Food & Beverage$8,400 (14.3%)
Travel$3,338 (5.7%)
Education$449.35 (0.8%)
Gifts$59.40 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $30,697 | 11 | 52.3% |
| Honoraria | $13,716 | 8 | 23.4% |
| Food and Beverage | $8,400 | 229 | 14.3% |
| Travel and Lodging | $3,338 | 15 | 5.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2,000 | 1 | 3.4% |
| Education | $449.35 | 16 | 0.8% |
| Gift | $59.40 | 1 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Xeris Pharmaceuticals, Inc. | $28,232 | 43 | $0 (2024) |
| LifeScan, Inc. | $12,714 | 14 | $0 (2019) |
| Merck Sharp & Dohme Corporation | $7,249 | 26 | $0 (2019) |
| Novo Nordisk Inc | $3,343 | 45 | $0 (2024) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $2,000 | 1 | $0 (2019) |
| SANOFI-AVENTIS U.S. LLC | $741.88 | 22 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $578.40 | 15 | $0 (2019) |
| Averitas Pharma Inc. | $484.01 | 8 | $0 (2024) |
| Abbott Laboratories | $482.24 | 23 | $0 (2024) |
| Corcept Therapeutics | $438.54 | 11 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $13,229 | 41 | Xeris Pharmaceuticals, Inc. ($12,424) |
| 2023 | $14,693 | 48 | Xeris Pharmaceuticals, Inc. ($13,682) |
| 2022 | $2,671 | 22 | Xeris Pharmaceuticals, Inc. ($2,090) |
| 2021 | $206.16 | 9 | AstraZeneca Pharmaceuticals LP ($80.35) |
| 2020 | $493.32 | 13 | Novo Nordisk Inc ($210.92) |
| 2019 | $7,800 | 39 | LifeScan, Inc. ($4,810) |
| 2018 | $7,775 | 50 | LifeScan, Inc. ($4,219) |
| 2017 | $11,791 | 59 | Merck Sharp & Dohme Corporation ($6,805) |
All Payment Transactions
281 individual payment records from CMS Open Payments — Page 1 of 12
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | Corcept Therapeutics | Korlym (Drug) | Food and Beverage | In-kind items and services | $28.18 | General |
| Category: Endocrinology | ||||||
| 12/18/2024 | Abbott Laboratories | FREESTYLE LIBRE 3 (Device) | Food and Beverage | In-kind items and services | $17.13 | General |
| Category: Diabetes Care | ||||||
| 12/10/2024 | Xeris Pharmaceuticals, Inc. | GVOKE HYPOPEN (Drug) | Honoraria | Cash or cash equivalent | $2,286.00 | General |
| Category: Diabetes | ||||||
| 12/10/2024 | Xeris Pharmaceuticals, Inc. | GVOKE HYPOPEN (Drug) | Travel and Lodging | Cash or cash equivalent | $42.20 | General |
| Category: Diabetes | ||||||
| 12/05/2024 | Xeris Pharmaceuticals, Inc. | GVOKE HYPOPEN (Drug) | Food and Beverage | In-kind items and services | $7.85 | General |
| Category: Diabetes | ||||||
| 12/02/2024 | Xeris Pharmaceuticals, Inc. | GVOKE HYPOPEN (Drug) | Honoraria | Cash or cash equivalent | $2,286.00 | General |
| Category: Diabetes | ||||||
| 10/29/2024 | Xeris Pharmaceuticals, Inc. | GVOKE HYPOPEN (Drug) | Food and Beverage | In-kind items and services | $121.84 | General |
| Category: Diabetes | ||||||
| 10/23/2024 | Averitas Pharma Inc. | QUTENZA (Drug) | Food and Beverage | In-kind items and services | $22.41 | General |
| Category: PAIN MANAGEMENT | ||||||
| 10/18/2024 | Xeris Pharmaceuticals, Inc. | GVOKE HYPOPEN (Drug) | Honoraria | Cash or cash equivalent | $2,286.00 | General |
| Category: Diabetes | ||||||
| 10/18/2024 | Xeris Pharmaceuticals, Inc. | GVOKE HYPOPEN (Drug) | Travel and Lodging | Cash or cash equivalent | $24.12 | General |
| Category: Diabetes | ||||||
| 10/15/2024 | Xeris Pharmaceuticals, Inc. | GVOKE HYPOPEN (Drug) | Food and Beverage | In-kind items and services | $95.85 | General |
| Category: Diabetes | ||||||
| 10/14/2024 | Abbott Laboratories | FREESTYLE LIBRE 3 (Device) | Food and Beverage | In-kind items and services | $12.88 | General |
| Category: Diabetes Care | ||||||
| 09/25/2024 | Abbott Laboratories | FREESTYLE LIBRE 3 (Device) | Food and Beverage | In-kind items and services | $48.23 | General |
| Category: Diabetes Care | ||||||
| 09/17/2024 | Xeris Pharmaceuticals, Inc. | GVOKE HYPOPEN (Drug) | Food and Beverage | In-kind items and services | $95.13 | General |
| Category: Diabetes | ||||||
| 09/11/2024 | Abbott Laboratories | FREESTYLE LIBRE 3 (Device) | Food and Beverage | In-kind items and services | $24.80 | General |
| Category: Diabetes Care | ||||||
| 09/11/2024 | Abbott Laboratories | FREESTYLE LIBRE 3 (Device) | Food and Beverage | In-kind items and services | $23.22 | General |
| Category: Diabetes Care | ||||||
| 08/20/2024 | Abbott Laboratories | FREESTYLE LIBRE 3 (Device) | Food and Beverage | In-kind items and services | $12.60 | General |
| Category: Diabetes Care | ||||||
| 07/29/2024 | SANOFI-AVENTIS U.S. LLC | TZIELD (Biological) | Food and Beverage | In-kind items and services | $33.05 | General |
| Category: Endocrine & Metabolic Diseases | ||||||
| 07/16/2024 | Abbott Laboratories | FREESTYLE LIBRE 3 (Device) | Food and Beverage | In-kind items and services | $6.80 | General |
| Category: Diabetes Care | ||||||
| 07/08/2024 | Lilly USA, LLC | JARDIANCE (Drug), ZEPBOUND | Food and Beverage | In-kind items and services | $18.93 | General |
| Category: Diabetes | ||||||
| 07/02/2024 | Xeris Pharmaceuticals, Inc. | GVOKE HYPOPEN (Drug) | Honoraria | Cash or cash equivalent | $2,286.00 | General |
| Category: Diabetes | ||||||
| 07/02/2024 | Xeris Pharmaceuticals, Inc. | GVOKE HYPOPEN (Drug) | Travel and Lodging | Cash or cash equivalent | $40.20 | General |
| Category: Diabetes | ||||||
| 06/27/2024 | Lilly USA, LLC | MOUNJARO (Drug), ZEPBOUND | Food and Beverage | In-kind items and services | $21.37 | General |
| Category: Diabetes | ||||||
| 06/23/2024 | Averitas Pharma Inc. | QUTENZA (Drug) | Food and Beverage | In-kind items and services | $185.90 | General |
| Category: PAIN MANAGEMENT | ||||||
| 06/23/2024 | GlaxoSmithKline, LLC. | — | Food and Beverage | In-kind items and services | $46.43 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 257 | 426 | $196,412 | $29,029 |
| 2022 | 6 | 246 | 403 | $165,571 | $27,739 |
| 2021 | 7 | 257 | 420 | $170,358 | $29,751 |
| 2020 | 6 | 232 | 366 | $157,771 | $23,709 |
Total Patients
992
Total Services
1,615
Medicare Billing
$110,228
Procedure Codes
25
All Medicare Procedures & Services
25 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 159 | 306 | $127,314 | $20,466 | 16.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 30 | 30 | $19,437 | $2,977 | 15.3% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 13 | 28 | $17,024 | $2,369 | 13.9% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 20 | 20 | $21,200 | $2,005 | 9.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 16 | 16 | $4,313 | $608.28 | 14.1% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Facility | 2023 | 19 | 26 | $7,124 | $604.49 | 8.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 143 | 276 | $103,396 | $18,879 | 18.3% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 21 | 37 | $20,461 | $2,936 | 14.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 27 | 27 | $15,484 | $2,752 | 17.8% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 15 | 15 | $14,460 | $1,578 | 10.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 19 | 21 | $5,047 | $939.31 | 18.6% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Facility | 2022 | 21 | 27 | $6,723 | $654.15 | 9.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 139 | 274 | $100,577 | $18,780 | 18.7% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Facility | 2021 | 38 | 38 | $22,888 | $3,679 | 16.1% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 22 | 37 | $19,869 | $3,038 | 15.3% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 11 | 12 | $6,102 | $1,275 | 20.9% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 11 | 11 | $9,106 | $1,172 | 12.9% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 21 | 24 | $5,648 | $1,151 | 20.4% |
| 95251 | Ambulatory continuous glucose (sugar) including interpretation and report for a minimum of 72 hours | Facility | 2021 | 15 | 24 | $6,168 | $656.14 | 10.6% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 125 | 225 | $80,465 | $11,886 | 14.8% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 25 | 56 | $29,176 | $4,589 | 15.7% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 41 | 41 | $30,669 | $4,180 | 13.6% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Facility | 2020 | 17 | 17 | $9,316 | $1,448 | 15.5% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 12 | 15 | $5,445 | $856.70 | 15.7% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2020 | 12 | 12 | $2,700 | $748.68 | 27.7% |
About Dr. Robert Zimmerman, MD
Dr. Robert Zimmerman, MD is a Endocrinology, Diabetes & Metabolism healthcare provider based in Cleveland, Ohio. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/13/2006. The National Provider Identifier (NPI) number assigned to this provider is 1689764706.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Robert Zimmerman, MD has received a total of $58,659 in payments from pharmaceutical and medical device companies, with $13,229 received in 2024. These payments were reported across 281 transactions from 32 companies. The most common payment nature is "Consulting Fee" ($30,697).
As a Medicare-enrolled provider, Zimmerman has provided services to 992 Medicare beneficiaries, totaling 1,615 services with total Medicare billing of $110,228. Data is available for 4 years (2020–2023), covering 25 distinct procedure/service records.
Ad
Practice Information
- Specialty Endocrinology, Diabetes & Metabolism
- Other Specialties Diabetes & Metabolism
- Location Cleveland, OH
- Active Since 10/13/2006
- Last Updated 02/04/2008
- Taxonomy Code 207RE0101X
- Entity Type Individual
- NPI Number 1689764706
Products in Payments
- GVOKE HYPOPEN (Drug) $26,093
- OneTouch (Device) $12,714
- Victoza (Drug) $2,165
- GVOKE PFS (Drug) $2,114
- CYCLOSET (Drug) $2,000
- QUTENZA (Drug) $484.01
- JARDIANCE (Drug) $475.35
- Korlym (Drug) $438.54
- FREESTYLE LIBRE 3 (Device) $368.24
- Minimed 670G System (Device) $303.98
- INVOKANA (Drug) $273.52
- JANUVIA (Drug) $264.10
- SOLIQUA (Drug) $230.98
- Ozempic (Drug) $204.65
- FARXIGA (Drug) $164.07
- SOLIQUA 100/33 (Biological) $158.55
- TZIELD (Biological) $150.50
- t-slim insulin pump (Device) $145.77
- t:slim X2 insulin pump (Device) $120.74
- RYBELSUS (Drug) $106.68
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Endocrinology, Diabetes & Metabolism Doctors in Cleveland
Kevin Pantalone, D.o, D.O
Endocrinology, Diabetes & Metabolism — Payments: $1.5M
Endocrinology, Diabetes & Metabolism $1.5M
Adi Mehta, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $216,001
Endocrinology, Diabetes & Metabolism $216,001
Dr. Allan Kennedy, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $158,447
Endocrinology, Diabetes & Metabolism $158,447
Christian Nasr, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $152,638
Endocrinology, Diabetes & Metabolism $152,638
Dr. Bartolome Burguera, Md, Phd, MD, PHD
Endocrinology, Diabetes & Metabolism — Payments: $92,204
Endocrinology, Diabetes & Metabolism $92,204
Marwan Hamaty, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $57,065
Endocrinology, Diabetes & Metabolism $57,065